Advanced Search
Contact | Corporate | Help

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Sponsors:
  • University of Michigan Cancer Center
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • HER-2 Positive Metastatic Breast Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: Docetaxel
  • Drug: Trastuzumab
  • Procedure: Erythromycin Breath Test (ERMBT)
Enrollment:
30

Additional information about NCT00146042.


SourceSolution © 2008-2012